Sclerosis in Multiple Sclerosis: Pathology, Lesion Types & Clinical Impact

Definition

Sclerosis (Greek *skleros* = hard) = pathological hardening/scarring. In MS, it refers to demyelinating lesions (plaques) that become gliotic (astrocytic scar) over time.

Pathological Sequence

  1. Inflammatory infiltrate: T-cells (CD4+ Th1/Th17, CD8+), B-cells, microglia cross BBB.
  2. Demyelination: Antibody/complement-mediated + macrophage stripping of myelin.
  3. Axonal transection: Acute (inflammatory) + chronic (energy failure).
  4. Gliosis: Astrocyte proliferation → dense glial scar (sclerotic plaque).
  5. Remyelination: Often incomplete; shadow plaques (thin myelin).

Lesion Classification

  • Active (acute): Gadolinium-enhancing on MRI; inflammatory cells present.
  • Chronic active (smoldering): Rim of microglial activation (paramagnetic rim on 7T MRI); slow expansion.
  • Chronic inactive: Gliotic scar, no enhancement, stable.
  • Cortical vs. White Matter: Cortical lesions harder to see; correlate with cognitive/physical disability.

Phenotypic Correlation

  • Relapsing-Remitting (RRMS): Focal inflammatory plaques; relapses = new Gd+ lesions.
  • Progressive (SPMS/PPMS): Diffuse neurodegeneration, chronic active lesions, cortical pathology, compartmentalized inflammation.

Imaging & Biomarkers

  • MRI: T2/FLAIR (lesion load), Gd+ (activity), brain atrophy (neurodegeneration).
  • CSF: Oligoclonal bands (intrathecal IgG synthesis).
  • Serum: Neurofilament light chain (NfL) – axonal injury marker.

Therapeutic Implication

DMTs target inflammation (reduce new sclerosis). Neuroprotection/remyelination strategies aim to limit chronic sclerosis progression. Early treatment = less accumulated sclerosis.

Multiple Sclerosis - Related Articles